In the long aftermath of a breast cancer diagnosis, the hardest treatment is often the one taken alone, at home, every day for five years. A sweeping analysis of American insurance records has revealed that fewer than one in three women with early-stage hormone-sensitive breast cancer maintained consistent endocrine therapy across the full recommended period — a finding that quietly unsettles the growing clinical movement to replace radiation with medication alone. The gap between what medicine prescribes and what human life permits is not a failure of will, but a reminder that sustained heali
Study reveals low long-term adherence to hormone therapy after breast cancer surgery
Patients experiencing treatment side effects including hot flashes, fatigue, joint pain, bone health effects, and cognitive changes may discontinue therapy, potentially increasing cancer recurrence risk.
Doctors prescribing and patients taking are not the same thing
Mark
So the headline is that people stop taking their cancer medicine. But what's the actual clinical consequence here?
Mimi
The consequence depends on which patients we're talking about. For someone who gets radiation, the local recurrence risk is already low. Missing some doses of hormone therapy is not ideal, but the radiation is still protecting that breast. For someone who skipped radiation to avoid the side effects and the time commitment—they're now relying entirely on the hormone therapy to prevent the cancer from coming back anywhere in the body. If they stop taking it, they lose that protection.
Luke
But the study doesn't actually show that nonadherence caused recurrence, right? It's a pharmacy claims analysis. It shows who filled prescriptions, not who got cancer again.
Mimi
That's correct. The study is a snapshot of what happened with medication possession. It doesn't follow patients forward to see who relapsed. That's a limitation the researchers acknowledge.
Mark
Why would skipping radiation make someone less likely to stick with pills?
Mimi
The researchers don't know for certain. One theory: patients who get radiation see their oncology team regularly during treatment. That contact, that accountability, might reinforce the importance of the hormone therapy. Patients who skip radiation might have less frequent check-ins.
Luke
Or it could be selection bias. Maybe patients who decline radiation are already skeptical of medical recommendations, or they have different priorities around quality of life. The data can't separate cause from correlation.
Mark
And the age finding—younger patients are worse at adherence. Why would that be?
Mimi
The study doesn't explain it. But you can imagine: younger women might have more competing demands—work, family, children. The side effects might feel more disruptive to an active life. And the cancer feels less urgent when you're 45 and the risk of recurrence is years away.
Luke
It's also worth noting that the study only goes up to age 64. So we don't actually know if older patients, who are the ones currently getting radiation omission in clinical practice, have better or worse adherence. That's a real gap.
Mark
So what should a doctor actually say to a patient considering skipping radiation?
Mimi
Based on this study, something like: "Radiation works. It reduces local recurrence. If we skip it, you're betting on taking this pill every day for five years. Our data shows most people don't do that. Are you confident you can?"
Luke
And the honest answer is probably: most people aren't confident. Which means radiation omission might not be the right choice for most patients, even if the clinical trials say it's safe.
Mimi
That's the real tension. The trials show you can omit radiation without compromising overall survival. But they assume perfect adherence to the pills. Real life doesn't work that way.
O Pulso
- A study of over 17,000 breast cancer patients found that annual adherence rates looked reassuring at 59–75%, but collapsed to just 28% when measured across the full five-year treatment window.
- Patients who skipped radiation therapy were twice as likely to fall dangerously below medication thresholds, raising urgent questions about whether omitting radiation simply shifts the burden — and the risk — onto daily pills.
- Younger patients, the very group increasingly targeted by radiation-omission clinical trials, showed 20–25% higher rates of nonadherence, exposing a troubling mismatch between evolving treatment strategy and real-world behavior.
- Side effects including hot flashes, joint pain, fatigue, bone loss, and cognitive changes accumulate over months and years, quietly eroding patients' willingness to continue a regimen whose benefits feel abstract against daily suffering.
- Researchers are now expanding the dataset to include Medicare patients, while clinicians are being urged to have frank, grounded conversations about what five years of daily medication truly demands before removing radiation from a treatment plan.
In the long aftermath of a breast cancer diagnosis, the hardest treatment is often the one taken alone, at home, every day for five years. A sweeping analysis of American insurance records has revealed that fewer than one in three women with early-stage hormone-sensitive breast cancer maintained consistent endocrine therapy across the full recommended period — a finding that quietly unsettles the growing clinical movement to replace radiation with medication alone. The gap between what medicine prescribes and what human life permits is not a failure of will, but a reminder that sustained healing asks something of patients that a single surgical moment does not.
A large analysis of American insurance records has exposed a quiet but consequential gap in breast cancer care: among more than 17,000 women with early-stage, hormone-sensitive breast cancer who underwent lumpectomy, fewer than 30 percent maintained consistent hormone therapy for the full five years recommended after surgery. The research, presented at the American Society for Radiation Oncology's annual meeting in September 2026, drew from commercial and Medicaid claims for patients aged 23 to 64, tracking pharmacy records to measure whether patients had enough medication on hand to follow their prescribed regimen.
The data revealed a deceptive pattern. Measured year by year, adherence looked relatively strong — between 59 and 75 percent of patients met the standard threshold in any single year. But tracked across all five years, the picture collapsed. Small lapses accumulated — a skipped month, a delayed refill — until most patients had fallen short of continuous adherence. Even at the most lenient measurement standard, only about half the group maintained consistent access to medication.
Two factors stood out. Patients who did not receive radiation were twice as likely to fall below the lowest possession threshold, suggesting that omitting radiation may not simply reduce treatment burden but shift it onto a regimen patients are less likely to sustain. Age compounded the problem: patients younger than 60 faced a 20 to 25 percent higher risk of nonadherence — precisely the population that newer clinical trials are targeting for radiation omission.
The side effects of long-term endocrine therapy help explain why adherence erodes. Hot flashes, fatigue, joint pain, bone loss, and cognitive changes can accumulate until the daily cost of medication outweighs a cancer risk that feels increasingly distant. Shannon Jiang, the radiation oncology resident who led the study at Washington University School of Medicine in St. Louis, put it directly: prescribing five years of therapy and a patient actually taking it for five years are not the same thing.
The study's authors plan to incorporate Medicare data to examine adherence in older patients — currently the group most often considered for radiation omission. In the meantime, the findings carry a clear message for clinicians: treatment plans must be built not only around what is medically optimal, but around what patients can realistically sustain across years of ordinary life.
A large analysis of insurance claims across the United States has surfaced a stubborn gap between what doctors prescribe and what patients actually take. Among more than 17,000 women with early-stage, hormone-sensitive breast cancer who underwent lumpectomy, fewer than 30 percent stuck with their prescribed hormone therapy for the full five years recommended after surgery. The finding matters because it challenges an assumption built into newer treatment approaches: that patients can reliably replace radiation therapy with long-term medication alone.
The research, presented at the American Society for Radiation Oncology annual meeting in September 2026, drew from commercial and Medicaid insurance records of patients aged 23 to 64. All had undergone lumpectomy and filled at least one prescription for endocrine therapy—the hormone-blocking medication that reduces the risk of cancer returning throughout the body. About 89 percent of the group also received radiation therapy. Researchers tracked pharmacy claims to calculate a medication possession ratio, a measure of whether patients had enough pills on hand to follow their prescribed regimen. The standard threshold for adherence was 80 percent possession over the five-year period.
When researchers looked at single years in isolation, the picture appeared far more encouraging. Between 59 and 75 percent of patients met the 80 percent threshold in any given year. But when the same patients were tracked across all five years, the numbers collapsed. The accumulation of lapses—a month or two skipped here, a refill delayed there—meant that by year five, most had fallen short of continuous adherence. The researchers also examined looser thresholds: 70, 60, and 50 percent possession. Even at the most lenient standard, only about half the group maintained consistent access to medication.
Two patterns emerged from the data. Patients who did not receive radiation therapy were significantly more likely to abandon their medication regimen. Those who skipped radiation were twice as likely to fall below the 50 percent possession threshold over time and showed higher nonadherence rates at the 60 and 70 percent benchmarks as well. The researchers could not determine why from the claims data alone—whether patients who declined radiation were also less committed to medication, whether they had less frequent contact with their oncology teams, or whether other differences in health care access played a role. But the association was clear.
Age also predicted adherence. Patients younger than 60 had a 20 to 25 percent higher risk of becoming nonadherent across all the thresholds studied. This finding carries particular weight as clinical trials increasingly explore omitting radiation in younger women with favorable tumor characteristics. If radiation is removed from the treatment plan, endocrine therapy becomes the sole systemic defense against recurrence—and the data suggest younger patients are precisely the group most likely to stop taking it.
The side effects of long-term hormone therapy help explain why. Endocrine therapy can trigger hot flashes, fatigue, joint pain, bone loss, and cognitive changes. For some patients, these effects accumulate over months and years until the burden of daily medication outweighs the abstract benefit of cancer prevention. Shannon Jiang, the radiation oncology resident who led the study at Washington University School of Medicine in St. Louis, noted the gap between clinical intention and lived reality. "Doctors prescribing endocrine therapy for five years and patients actually taking the medication for five years are not the same thing," she said. When radiation is omitted, that gap becomes a clinical problem.
The study was limited to patients under 65, so it cannot speak to the older population currently most likely to be considered for radiation omission. Jiang's team plans to add Medicare data to examine adherence in that group. For now, the findings suggest that clinicians counseling patients on radiation omission need to have candid conversations about what five years of daily medication actually entails—not just the side effects, but the practical difficulty of maintaining a regimen when the immediate threat feels distant. Jose Bazan, chair of the American Society for Radiation Oncology's breast cancer resource panel, framed it plainly: the goal is to choose a treatment plan that patients can realistically sustain over time, not one that looks good on paper but crumbles in the years that follow.
Citações Notáveis
When radiation therapy is omitted, endocrine therapy becomes an especially important part of the treatment strategy for preventing recurrence. We need to have realistic conversations with patients considering this approach about what long-term treatment and their quality of life will involve.— Shannon Jiang, MD, lead study author, Washington University School of Medicine
The evidence we use to guide de-escalation needs to be considered alongside what happens to patients over the years that follow.— Shannon Jiang, MD
Quer a matéria completa?
Leia o original em News-Medical ↗